Sirius has signed a collaborative agreement with the Assistance Publique -Hopitaux de Paris (AP-HP), to study genomic co-rrelations in severe sepsis patients.
The agreement focuses on the continued development of Sirius’ pharmacogenomic diagnostic. It is intended to assess responsiveness to recombinant human activated Protein-C in patients with severe sepsis at high risk of death.
Brad Popovich, President and CEO of Sirius, said: Access to AP-HP’s severe sepsis patients will be critical in the validation of Sirius’ sepsis biomarkers and we are delighted to be working with this internationally acclaimed research group.
Publique – Hopitaux de Paris is a public health establishment in Paris, with activities in the field of healthcare, teaching, medical research, prevention, health education and urgent medical assistance.